Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Tryptamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.73 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.73 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.69 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.69 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.66 |
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A known ✓ | Q03164 | 3/20 | 0.54 |
| ▸ | HTR7 | P34969 | 5/20 | 0.73 |
| ▸ | HTR1B | P28222 | 4/20 | 0.73 |
| ▸ | HTR6 | P50406 | 4/20 | 0.73 |
| ▸ | MPO | P05164 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | HTR1D | P28221 | 1/20 | 0.73 |
| ▸ | CTSK | P43235 | 1/20 | 0.73 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.73 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tryptamine SCHEMBL29693568 | 1.00 | HTR7 (0.73) | HTR7HTR1BHTR2CHTR6HTR2A | |
| Tryptamine SCHEMBL30426532 | 0.91 | HTR7 (0.83) | HTR7HTR1BHTR2CHTR6HTR2A | |
| Tryptamine SCHEMBL28751439 | 0.89 | CYP1A2 (0.81) | HTR7HTR1BHTR2CHTR6HTR2A | |
| Tryptamine SCHEMBL27094904 | 0.88 | HTR1B (0.78) | HTR7HTR1BHTR2CHTR6HTR2A | |
| Tryptamine SCHEMBL30812535 | 0.87 | HTR7 (0.76) | HTR7HTR1BHTR2CHTR6HTR2A | |
| Tryptamine SCHEMBL5298628 | 0.87 | HTR1B (0.76) | HTR7HTR1BHTR2CHTR6HTR2A | |
| Tryptamine SCHEMBL28985494 | 0.86 | CYP1A2 (0.81) | HTR7HTR1BHTR2CHTR6HTR2A | |
| Tryptamine SCHEMBL29373222 | 0.86 | HTR2A (1.00) | HTR7HTR1BHTR2CHTR6HTR2A | |
| Tryptamine SCHEMBL8714244 | 0.86 | HTR2A (1.00) | HTR7HTR1BHTR2CHTR6HTR2A | |
| Tryptamine SCHEMBL26725 | 0.86 | HTR2A (1.00) | HTR7HTR1BHTR2CHTR6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702007-A1 | INTRAVENOUS DIMETHYLTRYPTAMINE (DMT) ADMINISTRATION METHOD FOR TREATING, PREVENTING, AND/OR AMELIORATING DEPRESSION | Yale University (US) | 2026-03-04 | — | — | EP | claimed |
| WO-2024197022-A1 | INTRAVENOUS DIMETHYLTRYPTAMINE (DMT) ADMINISTRATION METHOD FOR TREATING, PREVENTING, AND/OR AMELIORATING DEPRESSION | YALE UNIVERSITY (US) | 2024-09-26 | — | — | WO | claimed |
| US-20230384333-A1 | GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-30 | — | — | US | disclosed |
| CN-117015712-A | GPCR screening method for identifying non-magic compound | 加利福尼亚大学董事会 | 2023-11-07 | — | — | CN | disclosed |
| EP-4229075-A1 | GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS | The Regents of the University of California (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022081631-A1 | GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230384333-A1 | GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS | HTR4, HTR6, HTR1A | HTR2C 6/4885HTR2A 5/4885HRH1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.